Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Transition Therapeutics Licenses Diabetes Regenerative Therapy

By Pharmaceutical Processing | August 24, 2004

TORONTO (August 23, 2004) — Transition Therapeutics Inc. has signed a licensing agreement with Novo Nordisk A/S to develop the Islet Neogenesis Therapy (“I.N.T.”) for the treatment of diabetes. The I.N.T. technology represents a novel approach to regenerate insulin producing cells in the body and is currently under development for the treatment of both type I and type II insulin dependent diabetics. The agreement includes an equity investment of CAN$ 6 million, upfront payments and development milestones potentially totaling up to US$ 48 million, commercial milestones and royalties. Transition had previously announced on June 24, 2004 Novo Nordisk’s decision to exercise its option to license Transition’s I.N.T. technology.

“The signing of this agreement with Novo Nordisk represents a key milestone for Transition and provides significant validation of our work to date,” said Tony Cruz, Chairman and CEO of Transition. “This relationship will allow us to advance key I.N.T.(TM) programs while working closely with a world leader in diabetes care.”

“The I.N.T.(TM) technology is supporting our efforts of developing a cure for diabetes. Although this project is at an early stage we are excited about the results obtained so far and look forward to exploring the potential of this technology”, said Dr. Peter Kurtzhals, Senior Vice President for Discovery at Novo Nordisk.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE